Extended survival rate for phase 2 breast cancer patients with new drug
Aug 25, 2011
Peregine Pharmaceuticals, a drug developer, recently found an extended survival rate with a combination of drugs for individuals who suffer from breast cancer, according to Proactive Investors.
The drug is bavituximab and when it is combined with docetaxel for patients that have phase 2 breast cancer, their survival median rate is 20.7 months, based on a recent study. A previous study stated only a 11.7 month median rate when the patients were treated with only chemotherapy or docetaxel.
"This newest data point from our prior Phase II signal-seeking trials is encouraging, and shows adding bavituximab to the standard chemotherapy docetaxel offers meaningful survival benefits to breast cancer patients," head of medical oncology at Peregrine, Dr. Kerstin B. Menander, told the news source.
According to the American Cancer Society, breast cancer is the second leading cause of cancer-related death, following only lung cancer. However, the fatality rate has decreased since 1990 due to breakthrough breast cancer news, and there are currently 2.5 million breast cancer survivors in the U.S. today.